...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Reduced Osmolarity Oral Rehydration Salts Solution in Children With Acute Watery Diarrhea
【24h】

Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Reduced Osmolarity Oral Rehydration Salts Solution in Children With Acute Watery Diarrhea

机译:多中心,随机,双盲临床试验,以评估降低的渗透压口服补液盐溶液对急性水样腹泻儿童的疗效和安全性

获取原文
           

摘要

Objective. To compare the efficacy of a reduced osmolarity oral rehydration salts (ORS) solution (75 mmol/L of sodium [Na], 20 mmol/L of potassium [K], 65 mmol/L of chloride, 10 mmol/L of citrate, and 75 mmol/L of glucose; osmolarity, 245 mosm/L) with that of the standard World Health Organization (WHO) ORS solution.Design. A multicenter, double-blind, randomized, controlled clinical trial conducted in children with acute diarrhea in 5 developing countries to measure mean stool output in the 24 hours after randomization, proportion of children who required unscheduled intravenous therapy, proportion of children who vomited in the first 24 hours, and diarrhea duration after randomization.Results. A total of 675 children who ranged in age from 1 to 24 months and who had acute diarrhea and dehydration were enrolled in the trial; 341 were randomized to receive reduced osmolarity ORS solution, and 334 were randomized to receive the WHO ORS solution. The mean (SE) stool output (g/kg) in the first 24 hours (reduced osmolarity ORS solution vs WHO ORS solution = 114 [4] vs 125 [5]) and during the total study period (reduced osmolarity ORS solution vs WHO ORS solution = 320 [18] vs 331 [18]) were comparable. The proportion of children who vomited in the first 24 hours (reduced osmolarity ORS solution vs WHO ORS solution = 58% vs 62%) and the diarrhea duration in the 2 treatment groups, compared by log rank test, were similar. The proportion of children who required unscheduled intravenous therapy was significantly lower in children who received reduced osmolarity ORS solution (10%) as compared with those who received the WHO ORS solution (15%; odds ratio = 0.6, 95% confidence interval = 0.4–1.0). There was no significant difference in the incidence of hyponatremia (serum Na 130 mmol/L) at 24 hours between the 2 treatment groups (11% in reduced osmolarity ORS solution group vs 9% in the WHO ORS solution group; odds ratio = 1.3; 95% confidence interval = 0.8–2.2). The frequency of patients with serum Na 125 mmol/L at 24 hours was 13 of 341 (4%) in children who were treated with reduced osmolarity ORS solution versus 7 of 334 (2%) in children who received the WHO ORS solution.Conclusions. Treatment with reduced osmolarity ORS solution was associated with a 33% reduction in the need for unscheduled intravenous therapy and had no apparent effect on stool output and illness duration when compared with treatment with the standard WHO ORS solution. Children with acute diarrhea, therefore, may benefit from a reduced osmolarity ORS solution. The results of trials that examine the efficacy and safety of reduced osmolarity ORS solution in adult patients with cholera have to be taken into consideration before consensus on composition of oral rehydration formulation can be reached.
机译:目的。为了比较降低渗透压的口服补液盐(ORS)溶液(75 mmol / L钠[Na],20 mmol / L钾[K],65 mmol / L氯化物,10 mmol / L柠檬酸盐)的功效,葡萄糖和75 mmol / L葡萄糖;渗透压为245 mosm / L)与标准的世界卫生组织(WHO)ORS溶液相同。在5个发展中国家的急性腹泻儿童中进行了一项多中心,双盲,随机对照临床试验,以测量随机化后24小时内的平均大便排出量,需要进行不定期静脉治疗的儿童比例,在呕吐中呕吐的儿童比例前24小时,随机分组后腹泻持续时间。共有675名年龄在1到24个月之间,患有急性腹泻和脱水的儿童参加了该试验; 341例患者随机接受降低的渗透压ORS溶液,334例患者随机接受WHO ORS溶液。前24小时(整个研究期间)(渗透压ORS溶液相对于WHO的降低)(渗透压ORS溶液相对于WHO ORS溶液的减少量= 114 [4]对125 [5])的平均(SE)大便产量(g / kg) ORS解决方案= 320 [18]与331 [18])具有可比性。通过对数秩检验比较,在两个治疗组中,最初24小时呕吐的儿童比例(渗透压ORS溶液比WHO ORS溶液减少= 58%vs 62%)和腹泻持续时间相似。与接受WHO ORS溶液治疗的儿童(15%;优势比= 0.6、95%置信区间= 0.4–15)相比,接受渗透压ORS溶液降低的儿童(10%)中需要不定期静脉治疗的儿童比例显着降低1.0)。 2个治疗组之间在24小时内的低钠血症发生率(血清Na <130 mmol / L)没有显着差异(降低渗透压的ORS溶液组为11%,而WHO ORS溶液组为9%;优势比= 1.3 ; 95%置信区间= 0.8–2.2)。在接受渗透压降低的ORS溶液治疗的儿童中,24小时血清Na <125 mmol / L的患者发生频率为341例中的13例(4%),而接受WHO ORS溶液的儿童中334例中有7例(2%)。结论。与标准WHO WHO ORS溶液相比,渗透压降低的ORS溶液治疗与计划外静脉治疗的需求减少了33%,并且对粪便量和病程没有明显影响。因此,患有急性腹泻的儿童可受益于降低渗透压的ORS溶液。在就口服补液配方的组成达成共识之前,必须考虑研究降低渗透压的ORS溶液对成人霍乱患者的疗效和安全性的试验结果。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号